Antisense Oligonucleotides Targeting MicroRNAs in Osteosarcoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteosarcoma lack effective targeted therapies, and there is a need for new approaches to address the drug resistance and metastasis associated with cancer stem cells expressing CD133, particularly in osteosarcoma.
Innovation Solution
Administration of antisense molecules specific for microRNAs miR-1, miR-10b, and miR-133a, which are upregulated in CD133+ osteosarcoma cells, to target and reduce their expression, thereby inhibiting chemoresistance and invasiveness, combined with conventional chemotherapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic agents are used to treat osteosarcoma, then tumor growth is inhibited, but drug resistance develops due to cancer stem cells expressing CD133
Solution Approach 1:
The patent uses antisense molecules as intermediaries to target and inhibit microRNAs (miR-1, miR-10b, miR-133a) that are upregulated in CD133+ osteosarcoma cells. These antisense molecules act as mediators between the therapeutic intervention and the cancer stem cells, specifically blocking the function of microRNAs that confer chemoresistance, thereby restoring drug sensitivity without directly affecting the chemotherapeutic agents themselves
2Adaptability or versatility
If targeted therapy approaches are developed to address cancer stem cells, then drug resistance can be overcome, but no targeted therapy is currently available for osteosarcoma
Solution Approach 1:
The patent changes the therapeutic parameter from conventional chemotherapy targeting bulk tumor cells to antisense molecule therapy targeting specific microRNAs in cancer stem cells. By identifying and targeting the specific microRNA profile (miR-1, miR-10b, miR-133a) upregulated in CD133+ osteosarcoma cells, the invention creates a targeted therapy that addresses the root cause of chemoresistance while being manufacturable through established antisense oligonucleotide synthesis methods
3Ease of operation
If cancer stem cells are not targeted, then treatment is simpler, but metastasis and drug resistance persist
Solution Approach 1:
The patent extracts and specifically targets the pathogenic microRNA components (miR-1, miR-10b, miR-133a) that are responsible for cancer stem cell properties, chemoresistance, and metastasis in CD133+ osteosarcoma cells. By removing or inhibiting these specific microRNA molecules through antisense therapy, the treatment addresses metastasis and drug resistance without requiring complex multi-modal interventions, thus maintaining relative treatment simplicity while eliminating harmful effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of antisense molecules targeting miR-1, miR-10b, and miR-133a effectively reduces the malignant phenotypes of osteosarcoma cells, enhancing drug sensitivity and inhibiting tumor growth and metastasis, offering a promising new therapeutic strategy for osteosarcoma treatment.
Implementation Method 1
antisense molecules specific for microRNAs miR-1, miR-10b, and miR-133a, which are upregulated in CD133+ osteosarcoma cells, to target and reduce their expression
Data Source
AI summary
Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma.